Urate-Lowering Therapy May Lower Cardiovascular Risk

Hyperuricemia is associated with risk for CVD, and many studies show excess risk (CVD and all-cause mortality) for men with gout.
n = 40,000
2646 had gout, 55% of which were txed with urate-lowering therapy, 45% untreated
Followed for mean of 6.5 years
CVD- and all-cause-mortality did not differ between gout vs non-gout, but gout pts on urate-lowering tx had:
– lower all-cause mortality (HR 0.5)
– lower CVD-related mortality (HR 0.3)
Conclusion:  treating pts with hyperuricemia has effects beyond gout; randomized trials are needed to test the idea that urate-lowering therapy should be given to hyperuricemic patients regardless of gout presence.
J Rheumatol 2015 Sep; 42:1694

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s